Lovastatin enhances phenylbutyrate-induced MR-visible glycerophosphocholine but not apoptosis in DU145 prostate cells

Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids

Volumn 1771, Issue 9, 2007, Pages 1166-1176

  Milkevitch, Matthew ^a   Jeitner, Thomas M ^b   Beardsley, Nancy J ^a   Delikatny, E James ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Apoptosis; Differentiation; Glycerophosphocholine; HMG CoA reductase inhibitor; Lovastatin; NMR; NMR visible lipids; Phenylbutyrate

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; CELL MARKER; DYE; FAT DROPLET; GLYCEROPHOSPHORYLCHOLINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NUCLEOSIDE TRIPHOSPHATE;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; MALE; NUCLEAR MAGNETIC RESONANCE; PERFUSION; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEPLETION; PROTON NUCLEAR MAGNETIC RESONANCE;

ANIMALS; APOPTOSIS; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; ENZYME ACTIVATION; GLYCEROPHOSPHATES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCLUSION BODIES; LIPIDS; LOVASTATIN; MALE; NUCLEAR MAGNETIC RESONANCE, BIOMOLECULAR; PHENYLBUTYRATES; PHOSPHORYLCHOLINE; PROSTATIC NEOPLASMS;

EID: 34548626666     PISSN: 13881981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbalip.2007.05.010     Document Type: Article

References (69)

1. Milkevitch M., Shim H., Pilatus U., Pickup S., Wehrle J.P., Samid D., Poptani H., Glickson J.D., and Delikatny E.J. Increases in NMR-visible lipid and glycerophophocholine during phenylbutyrate-induced apoptosis in human prostate cancer cells. Biochim. Biophys. Acta 1734 (2005) 1-12
2. Delikatny E.J., Roman S.K., Hancock R., Jeitner T.M., Lander C.M., Rideout D.C., and Mountford C.E. Tetraphenylphosphonium chloride induced MR-visible lipid accumulation in a malignant human breast cell line. Int. J. Cancer 67 (1996) 72-79
3. Delikatny E.J., Cooper W.A., Brammah S., Sathasivam N., and Rideout D.C. Nuclear magnetic resonance-visible lipid induced by cationic lipophilic chemotherapeutic agents are accompanied by increased lipid droplet formation and damaged mitochondria. Cancer Res. 62 (2002) 1394-1400
4. Delikatny E.J., Lander C.M., Jeitner T.M., Hancock R., and Mountford C.E. Modulation of MR-visible mobile lipid levels by cell culture conditions and correlations with chemotactic response. Int. J. Cancer 65 (1996) 238-245
5. Delikatny E.J., van Holst Pellekaan C.J., and King N.J.C. Autologous lymphocyte-monocyte co-culture increases NMR-visible and cytoplasmic lipids in the absence of increased markers of lymphocyte activation. Biochim. Biophys. Acta 1533 (2001) 243-254
6. Blankenberg F.G., Katsikis P.D., Storrs R.W., Beaulieu C., Spielman D., Chen J.Y., Naumovski L., and Tait J.F. Quantitative analysis of apoptotic cell death using proton nuclear magnetic resonance spectroscopy. Blood 89 (1997) 3778-3786
7. Al-Saffar N.M., Titley J.C., Robertson D., Clarke P.A., Jackson L.E., Leach M.O., and Ronen S.M. Apoptosis is associated with triacylglycerol accumulation in Jurkat T-cells. Br. J. Cancer 86 (2002) 963-970
8. 1H NMR spectroscopy. Cell Death Differ. 8 (2001) 219-224
9. Di Vito M., Lenti L., Knijn A., Iorio E., D'Agostino F., Molinari A., Calcabrini A., Stringaro A., Meschini S., Arancia G., Bozzi A., Strom R., and Podo F. 1H NMR-visible mobile lipid domains correlate with cytoplasmic lipid bodies in apoptotic T-lymphoblastoid cells. Biochim. Biophys. Acta 1530 (2001) 47-66
10. 1H NMR Detects polyunsaturated fatty acid accumulation during gene therapy of glioma: implications for the in vivo detection of apoptosis. Nat. Med. 5 (1999) 1323-1327
11. Griffin J.L., Lehtimaki K.K., Valonen P.K., Grohn O.H.J., Kettunen M.I., Yla-Herttula S., Pitkanen A., Nicholson J.K., and Kauppinen R.A. Assignment of 1H nuclear magnetic resonance visible polyunsaturated fatty acids in BT4C gliomas undergoing ganciclovir-thymidine kinase gene therapy-induced programmed cell death. Cancer Res. 63 (2003) 3195-3201
12. Iorio E., Di Vito M., Spadaro F., Ramoni C., Lococo E., Carnevale R., Lenti L., Strom R., and Podo F. Triacsin C inhibits the formation of 1H NMR-visible mobile lipids and lipid bodies in HuT 78 apoptotic cells. Biochim. Biophys. Acta 1634 (2003) 1-14
13. Barba I., Cabañas M.E., and Arús C. The relationship between nuclear magnetic resonance-visible lipids, lipid droplets, and cell proliferation in cultured C6 cells. Cancer Res. 59 (1999) 1861-1868
14. Perez Y., Lahrech H., Cabanas M.E., Barnadas R., Sabes M., Remy C., and Arus C. Measurement by nuclear magnetic resonance diffusion of the dimensions of the mobile lipid compartment in C6 cells. Cancer Res. 62 (2002) 5672-5677
15. Gilbert J., Baker S.D., Bowling M.K., Grochow L., Figg W.D., Zabelina Y., Donehower R.C., and Carducci M.A. A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin. Cancer Res. 7 (2001) 2292-2300
16. Gore S.D., Weng L.J., Zhai S., Figg W.D., Donehower R.C., Dover G.J., Grever M., Griffin C.A., Grochow L.B., Rowinsky E.K., Zabalena Y., Hawkins A.L., Burks K., and Miller C.B. Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin. Cancer Res. 7 (2001) 2330-2339
17. Gore S.D., Weng L.J., Figg W.D., Zhai S., Donehower R.C., Dover G., Grever M.R., Griffin C., Grochow L.B., Hawkins A., Burks K., Zabelena Y., and Miller C.B. Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin. Cancer Res. 8 (2002) 963-970
18. Jung M. Inhibitors of histone deacetylase as new anticancer agents. Curr. Med. Chem. 8 (2001) 1505-1511
19. Davis T., Kennedy C., Chiew Y.E., Clarke C.L., and deFazio A. Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells. Clin. Cancer Res. 6 (2000) 4334-4342
20. Samid D., Wells M., Greene M.E., Shen W., Palmer C.N., and Thibault A. Peroxisome proliferator-activated receptor gamma as a novel target in cancer therapy: binding and activation by an aromatic fatty acid with clinical antitumor activity. Clin. Cancer Res. 6 (2000) 933-941
21. Han S., Wada R.K., and Sidell N. Differentiation of human neuroblastoma by phenylacetate is mediated by peroxisome proliferator-activated receptor gamma. Cancer Res. 61 (2001) 3998-4002
22. Samid D., Ram Z., Hudgins W.R., Shack S., Liu L., Walbridge S., Oldfield E.H., and Myers C.E. Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. Cancer Res. 54 (1994) 891-895
23. Castillo M., Martinez-Cayuela M., Zafra M.F., and Garcia-Peregrin E. Effect of phenylalanine derivatives on the main regulatory enzymes of hepatic cholesterogenesis. Mol. Cell. Biochem. 105 (1991) 21-25
24. Prasanna P., Thibault A., Liu L., and Samid D. Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells. J. Neurochem. 66 (1996) 710-716
25. Glunde K., Ackerstaff E., Natarajan K., Artemov D., and Bhujwalla Z.M. Real-time changes in 1H and 31P NMR spectra of malignant human mammary epithelial cells during treatment with the anti-inflammatory agent indomethacin. Magn. Reson. Med. 48 (2002) 819-825
26. Natarajan K., Mori N., Artemov D., Aboagye E.O., Chacko V.P., and Bhujwalla Z.M. Phospholipid profiles of invasive human breast cancer cells are altered towards a less invasive phospholipid profile by the anti-inflammatory agent indomethacin. Adv. Enzyme Regul. 40 (2000) 271-284
27. Dimitroulakos J., Nohynek D., Backway K., Hedley D.W., Yeger H., Freedman M.H., Minden M.D., and Penn L.Z. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood 93 (1999) 1308-1318
28. Alberts A.W. Discovery, biochemistry and biology of lovastatin. Am. J. Cardiol. 62 (1988) 10J-15J
29. Chan K.K.W., Oza A.M., and Siu L.L. The statins as anticancer agents. Clin. Cancer Res. 9 (2003) 10-19
30. Alonso D.F., Farina H.G., Skilton G., Gabri M.R., De Lorenzo M.S., and Gomez D.E. Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res. Treat. 50 (1998) 83-93
31. Broitman S.A., Wilkinson IV J., Cerda S., and Branch S.K. Effects of monoterpenes and mevinolin on murine colon tumor CT-26 in vitro and its hepatic "metastases" in vivo. Adv. Exp. Med. Biol. 401 (1996) 111-130
32. Feleszko W., Zagozdzon R., Golab J., and Jakobisiak M. Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in mice. Eur. J. Cancer 34 (1998) 406-411
33. Sumi S., Beauchamp R.D., Townsend Jr. C.M., Pour P.M., Ishizuka J., and Thompson J.C. Lovastatin inhibits pancreatic cancer growth regardless of RAS mutation. Pancreas 9 (1994) 657-661
34. Rubins J.B., Greatens T., Kratzke R.A., Tan A.T., Polunovsky V.A., and Bitterman P. Lovastatin induces apoptosis in malignant mesothelioma cells. Am. J. Respir. Crit. Care Med. 157 (1998) 1616-1622
35. Macaulay R.J., Wang W., Dimitroulakos J., Becker L.E., and Yeger H. Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro. J. Neuro-oncol. 42 (1999) 1-11
36. Agarwal B., Bhendwal S., Halmos B., Moss S.F., Ramey W.G., and Holt P.R. Lovastatin augments apoptosis induced by chemotherapeutic agents in colon cancer cells. Clin. Cancer Res. 5 (1999) 2223-2229
37. Padayatty S.J., Marcelli M., Shao T.S., and Cunningham G.R. Lovastatin-induced apoptosis in prostate stromal cells. J. Clin. Endocrinol. Metab. 82 (1997) 1434-1439
38. Xia Z., Tan M.M., Wong W.W., Dimitroulakos J., Minden M.D., and Penn L.Z. Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia (Baltimore) 15 (2001) 1398-1407
39. Marcelli M., Cunningham G.R., Haidacher S.J., Padayatty S.J., Sturgis L., Kagan C., and Denner L. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LnCaP. Cancer Res. 58 (1998) 76-83
40. Reedquist K.A., Pope T.K., and Roess D.A. Lovastatin inhibits proliferation and differentiation and causes apoptosis in lipopolysaccharide-stimulated murine B Cells. Biochem. Biophys. Res. Commun. 211 (1995) 665-670
41. Perez-Sala D., and Mollinedo F. Inhibition of isoprenoid biosynthesis induces apoptosis in human promyelocytic HL-60 cells. Biochem. Biophys. Res. Commun. 199 (1994) 1209-1215
42. Rao S., Lowe M., Herliczek T.W., and Keyomarsi K. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene 17 (1998) 2393-2402
43. Gray-Bablin J., Rao S., and Keyomarsi K. Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cells occurs in a cell cycle-independent fashion. Cancer Res. 57 (1997) 604-609
44. Giermasz A., Makowski M., Kozlowska E., Nowis D., Maj M., Jalili A., Feleszko W., Wojcik C., Dabrowska A., Jakobisiak M., and Golab J. Potentiating antitumor effects of a combination therapy with lovastatin and butyrate in the Lewis lung carcinoma model in mice. Int. J. Cancer 97 (2002) 746-750
45. Sora M.K., Kruszewski A.A., Stoklosa T., Czyzyk J., Lasek W., Malejczyk J., and Jakobisiak M. Synergistic antiproliferative activity of tumor necrosis factor alpha (TNF-α) and lovastatin. Arch. Immunol. Ther. Exp. (Warsz) 42 (1994) 269-274
46. Feleszko W., Lasek W., Golab J., and Jakobisiak M. Synergistic antitumor activity of tumor necrosis factor-alpha and lovastatin against MmB16 melanoma in mice. Neoplasma 42 (1995) 69-74
47. Soma M.R., Pagliarini P., Butti G., Paoletti R., Paoletti P., and Fumagalli R. Simavastatin, an inhibitor of cholesterol biosynthesis, shows a synergistic effect with N,N′-bis(2-chloroethyl)-N-nitrosourea and β-interferon on human glioma cells. Cancer Res. 52 (1992) 4348-4355
48. Pilatus U., Shim H., Artemov D., Davis D., van Zijl P.C., and Glickson J.D. Intracellular volume and apparent diffusion constants of perfused cancer cell cultures, as measured by NMR. Magn. Reson. Med. 37 (1997) 825-832
49. van Zijl P.C.M., Moonen C.T.W., Faustino P., Pekar J., Kaplan O., and Cohen J.S. Complete separation of intracellular and extracellular information in NMR spectra of perfused cells by diffusion-weighted spectroscopy. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 3228-3232
50. Arias-Mendoza F., Smith M.R., and Brown T.R. Predicting treatment response in non-Hodgkin's lymphoma from the pretreatment tumor content of phosphoethanolamine plus phosphocholine. Acad. Radiol. 11 (2004) 368-376
51. Naressi A., Couturier C., Devos J.M., Janssen M., Mangeat C., de Beer R., and Graveron-Demilly D. Java-based graphical user interface for the MRUI quantitation package. MAGMA 12 (2001) 141-152
52. Vanhamme L., van den Boogaart A., and Van Huffel S. Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J. Magn. Reson. 129 (1997) 35-43
53. Feleszko W., Jalili A., Olszewska D., Mlynarczuk I., Grzela T., Giermasz A., and Jakobisiak M. Synergistic interaction between highly specific cyclooxygenase-2 inhibitor, MF-tricyclic and lovastatin in murine colorectal cancer cell lines. Oncol. Report. 9 (2002) 879-885
54. Feleszko W., Balkowiec E.Z., Sieberth E., Marczak M., Dabrowska A., Giermasz A., Czajka A., and Jakobisiak M. Lovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis. Int. J. Cancer 81 (1999) 560-567
55. Holstein S.A., and Rohl R.J. Interaction of cytosine arabinoside and lovastatin in human leukemia cells. Leuk. Res. 25 (2001) 651-660
56. Bardeleben R.V., Dunkern T., Kaina B., and Fritz G. The HMG-CoA reductase inhibitor lovastatin protects cells from the antineoplastic drugs doxorubicin and etoposide. Int. J. Mol. Med. 10 (2002) 473-479
57. Castillo M., Zafra M.F., and Garcia-Peregrin E. Inhibition of brain and liver 3-hydroxy-3-methylglutaryl-CoA reductase and mevalonate-5-pyrophosphate decarboxylase in experimental hyperphenylalaninemia. Neurochem. Res. 13 (1988) 551-555
58. Kaneko I., Hazama-Shimada Y., and Endo A. Inhibitory effects on lipid metabolism in cultured cells of ML-236B, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Eur. J. Biochem. 87 (1978) 313-321
59. Mosley S.T., Kalinowski S.S., Shafer B.L., and Tanaka R.D. Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens. J. Lipid Res. 30 (1989) 1411-1420
60. Bensch W.B., Ingebriten T.S., and Diller E.R. Lack of correlation between the rate of cholesterol biosynthesis and the activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase in rats and in fibroblasts treated with ML-236B. Biochem. Biophys. Res. Commun. 82 (1978) 247-254
61. Williams M.L., Menon G.K., and Hanley K.P. HMG-CoA reductase inhibitors perturb fatty acid metabolism and induce peroxisomes in keratinocytes. J. Lipid Res. 33 (1992) 193-208
62. Field F.J., Born E., Murthy S., and Mathur S.N. Regulation of sterol regulatory element-binding proteins by cholesterol flux in CaCo-2 cells. J. Lipid Res. 42 (2001) 1687-1698
63. Field F.J., Born E., Murthy S., and Mathur S.N. Regulation of sterol regulatory element-binding proteins in hamster intestine by changes in cholesterol flux. J. Biol. Chem. 276 (2001) 17576-17583
64. Brown M.S., Faust J.R., and Goldstein J.L. Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin(ML-236B). J. Biol. Chem. 253 (1978) 1121-1128
65. Fears R., Richards D.H., and Ferres H. The effect of compactin, a potent inhibitor of 3-hydroxy-3-methylglutaryl conenzyme A reductase activity on cholesterologenesis and serum cholesterol levels in rats and chicks. Atherosclerosis 35 (1980) 439-449
66. 31P MR spectroscopy study using a continuous bioreactor system. Magn. Reson. Med. 33 (1995) 422-426
67. Menschikowski M., Hagelgans A., Heyne B., Hempel U., Neumeister V., Goez P., Jaross W., and Siegert G. Statins potentiate the IFN-gamma-induced upregulation of group IIA phospholipase A2 in human aortic smooth muscle cells and HepG2 hepatoma cells. Biochim. Biophys. Acta 1733 (2005) 157-171
68. Ackerstaff E., Pflug B.R., Nelson J.B., and Bhujwalla Z.M. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res. 61 (2001) 3599-3603
69. Quintero M., Cabanas M.E., and Arus C. A possible cellular explanation for the NMR-visible mobile lipid (ML) changes in cultured C6 glioma cells with growth. Biochim. Biophys. Acta 1771 (2007) 31-44